Author(s): Wahyuni, Ajeng Diantini, Mohammad Ghozali, I Sahidin

Email(s): ajeng.diantini@unpad.ac.id

DOI: 10.52711/0974-360X.2022.00068   

Address: Wahyuni1,2, Ajeng Diantini1*, Mohammad Ghozali3, I Sahidin4
1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Indonesia.
2Department of Pharmacology, Faculty of Pharmacy, Universitas Halu Oleo, Kendari, Indonesia.
3Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Jatinangor, Indonesia.
4Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Universitas Halu Oleo, Kendari, Indonesia.
*Corresponding Author

Published In:   Volume - 15,      Issue - 1,     Year - 2022


ABSTRACT:
We reviewed about the Triple-negative breast cancer (TNBC) and its treatment. We collected credible data from scientific database such as google scholar and Pubmed from published literatures between 2015 to 2020. According the collected literature, TNBC is one of breast cancer type can be found in women with breast cancer. It estimated about 170.000 of TNBC cases worldwide. The ER-/PR-/HER2- TNBC is the character for TNBC, and it has the poorest prognosis among other breast cancer. The risk factor of TNBC is gender, age, breastfeeding status, and special race such as African-American and Hispanic. Besides, the BRCA-1 mutation is related to TNBC. The treatment of TNBC is including surgery and radiotherapy, chemotherapy, and targeted therapy. The surgery, including BCS (Breast-conserving surgery) or called as lumpectomy and mastectomy; chemotherapy agent sensitive to TBNC, including alkylator agents, anthracyclines, taxanes, platinum-based chemotherapy, vinca alkaloids, and antimetabolites; as well targeted therapy such as PARP1 and PARP2 inhibitor, CDK (Cyclin-dependent kinase) inhibitor, p%3 inhibitor, CHK1 inhibitor, androgen antagonist, DNMT1 (DNA Methyltransferase 1) inhibitor, Anti-EGFR, PI3K/AKT/mTOR inhibitor, and anti-VEGF. These treatments are used both in early and metastatic stage of TNBC, alone or in combination.


Cite this article:
Wahyuni, Ajeng Diantini, Mohammad Ghozali, I Sahidin. A Review of Current treatment for Triple-Negative Breast Cancer (TNBC). Research Journal of Pharmacy and Technology. 2022; 15(1):409-8. doi: 10.52711/0974-360X.2022.00068

Cite(Electronic):
Wahyuni, Ajeng Diantini, Mohammad Ghozali, I Sahidin. A Review of Current treatment for Triple-Negative Breast Cancer (TNBC). Research Journal of Pharmacy and Technology. 2022; 15(1):409-8. doi: 10.52711/0974-360X.2022.00068   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-1-68


REFERENCES:
1.    Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various Types and Management of Breast Cancer: An Overview. J Adv Pharm Technol Res. 2010 Apr-Jun; 1(2): 109–126.
2.    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin 2018;68:394–424.
3.    Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014 Aug 10; 5(3): 283–298.
4.    Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, Shi W, Jiang J, Yao PP, Zhu HP. Risk Factors and Preventions of Breast Cancer. Int J Biol Sci. 2017; 13(11): 1387–1397.
5.    Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V, Matthews R, Owens C, Okoli J, Beech DJ, Piyathilake CJ, Reddy SP, Rao VN. Triple Negative Breast Cancer – An Overview. Hereditary Genet. 2013; 2013(Suppl 2): 001.
6.    Mehanna J, Haddad FGH, Eid R, Lambertini M, Kourie HR. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Womens Health. 2019; 11: 431–437.
7.    De Rujiter TC, Veeck J, de Hoon JPJ, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011 Feb; 137(2):183-192.
8.    Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016 Jun 16;11(6):e0157368.
9.    Ma H, Ursin G, Xu X, Lee E, Togawa K, Duan L, Lu Y, Maloon KE, Marchbanks PA, McDonald JA, Simon MS, Folger SG, Sullivan-Halley J, Deapen DM, Press MF, Bernstein L. Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. Breast Cancer Research. 2017; 19(6):1-14
10.    Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, Villarreal-Garza C, González-Angulo AM, Bargalló E, Aguilar JL, Mohar A, Arrieta Ó. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011 Aug 15;117(16):3658-69.
11.    Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE. Risk Factors for Triple-Negative Breast Cancer in Women Under Age 45. Cancer Epidemiol Biomarkers Prev. 2009 Apr; 18(4): 1157–1166.
12.    Gadi VK, Davidson NE. Practical Approach to Triple-Negative Breast Cancer. Journal of Oncology Practice. 2017; 13(5): 293-300
13.    Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019; 30: 1194–1220.
14.    Cardoso F, Senkus F, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Lopez BA, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology 29: 1634–1657.
15.    Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015 Jun; 12(2): 106–116.
16.    Fajdic J, Djurovic D, Gotovac N, Hrgovic. Criteria and Procedures for Breast Conserving Surgery. Acta Inform Med. 2013 Mar; 21(1): 16–19.
17.    Rahman GA. Breast Conserving Therapy: A surgical Technique where Little can Mean More. J Surg Tech Case Rep. 2011 Jan-Jun; 3(1): 1–4.
18.    Kim K, Park HJ, Shin KH, Kim JH, Choi DH, Park W, Ahn SD, Kim SS, Kim JH, Kim J. Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23. Cancer Res Treat. 2018 Oct; 50(4): 1316–1323.
19.    Wang SE, Sun YD, Zhao SJ, Wei F, Yang G. Breast conserving surgery (BCS) with adjuvant radiation therapy showed improved prognosis compared with mastectomy for early staged triple negative breast cancer patients Running title: BCS had better prognosis than mastectomy for early TNBC patients. Math Biosci Eng. 2019 Sep 26;17(1):92-104.
20.    Lubis AF. 2019. Farmakoterapi Penyakit Kanker. WR Publishing: Yogyakarta.
21.    Ralhan R, Kaur J. Alkylating agents and cancer therapy. Expert Opin. Ther. Patents. 2007; 17(9): 1061-1075.
22.    Shimada K, Ishikawa T, Kita K, Narui K, Sugae S, Shimizu D, Tanabe M, Sasaki T, Chishima T, Ichikawa Y, Endo I. Neoadjuvant Docetaxel/Cyclophosphamide in Triple-negative Breast Cancer: Predictive Value of Class III-β Tubulin and Non-basal Subtype. ANTICANCER RESEARCH. 2015; 35: 907-912.
23.    Halim A, Wahba H. Cisplatin-ifosfamide combination chemotherapy in metastatic triple-negative, anthracycline- and taxane-pretreated breast cancer patients; a phase II study. J BUON. 2012 Apr-Jun;17(2):254-8.
24.    Chen TC, Cho HY, Wang W, Barath M, Sharma N, Hofman FM, Schönthal AH. A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. Mol Cancer Ther. 2014 May;13(5):1181-93.
25.    Narui K, Ishikawa T, Shimizu D, Yamada A, Tanabe M, Sasaki T, Oba MS, Morita S, Nawata S, Kida K, Mogaki M, Doi T, Tsugawa K, Ogata H, Ota T, Kosaka Y, Sengoku N, Kuranami M, Niikura N, Saito Y, Suzuki Y, Suto A, Arioka H, Chishima T, Ichikawa Y, Endo I, Tokuda Y. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. Breast. 2019 Oct;47:1-9.  
26.    Pandy JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, Que FVF. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer. 2019; 19:1-9.
27.    Mustacchi G, De Laurentiis M. The role of taxanes in triple-negative breast cancer: literature review. Drug Des Devel Ther. 2015; 9: 4303–4318.
28.    Kaya V, Yildirim M, Yazici G, Gunduz S, Bozcuk H, Paydas S. Effectiveness of Platinum-Based Treatment for Triple Negative Metastatic Breast Cancer: a Meta-Analysis. Asian Pac J Cancer Prev. 2018; 19(5): 1169–1173.
29.    Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE. Platinum-based chemotherapy in triple-negative breast cancer. Annals of Oncology. 2008; 9(11):1847-1852.
30.    Cerrito MG, De Giorgi M, Pelizzoni D, Bonomo SM, Digiacomo N, Scagliotti A, Bugarin C, Gaipa G, Grassilli E, Lavitrano M, Giovannoni R, Bidoli P, Cazzaniga ME. Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. Oncotarget. 2018 Jun 8; 9(44): 27448–27459.
31.    Li M, Fan Y, Li Q, Zhang P, Yuan P, Ma F, Wang J, Luo Y, Cai R, Chen S, Li Q, Xu B. Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment. Medicine (Baltimore). 2015 Oct; 94(43): e1928.
32.    O’Reilly EA, Gubbins L, Sharma S, Tully R, Guang MHZ, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M, McCann A. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clinical. 2015; 3:257-275.
33.    Ozkan M, Berk V, Kaplan MA, Benekli M, Coskun U, Bilici A, Gumus M, Alkis N, Dane F, Ozdemir NY, Colak D, Dikilitas M. Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience. Neoplasma. 2012;59(1):38-42.
34.    Koshy N, Quispe D, Shi R, Mansour R, Burton GV. Cisplatin–gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. The Breast. 2010; 19(3):246-248.
35.    Li Y, Zhou Y, Mao F, Lin Y, Zhang X, Shen S, Sun Q. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis. Breast Cancer Res Treat. 2020 Feb;179(3):533-542.
36.    Liang X, Di L, Song G, Yan Y, Wang C, Jiang H, Li H. Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer. Chin J Cancer Res. 2014 Oct; 26(5): 550–557.
37.    Wei CW, Yu YL, Chen YH, Hung YT, Yiang GT. Anticancer effects of methotrexate in combination with α tocopherol and α tocopherol succinate on triple negative breast cancer. Oncol Rep. 2019 Mar;41(3):2060-2066.  
38.    El Kady MS, El Nasr K, Osman MAM, Ellithy M. Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: A phase III study. Journal of Clinical Oncology. 2015; 33 (15_suppl): e12087-e12087.
39.    Nicolas E, Bertucci F, Sebatier R, Gonçalves A. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? Cancers (Basel). 2018 Dec; 10(12): 506.
40.    Jhan JR, Andrechek ER. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics. 2017 Nov; 18(17): 1595–1609.
41.    Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, Cao S, Li X. Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis. Front Pharmacol. 2018; 9: 909.
42.    Dziadkowiec KN, Gasiorowska E, Nowak-Markwitz E, Jankowska A. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny. 2016 Dec; 15(4): 215–219.
43.    Exman P, Barroso-Sousa R, Tolaney SM. Evidence to date: talazoparib in the treatment of breast cancer. Onco Targets Ther. 2019 Jul 2;12:5177-5187.
44.    Guo XX, Wu HL, Shi HY, Su L, Zhang X. The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Manag Res. 2018 Aug 10;10:2553-2562.
45.    Caulfiled SE, Davis CE, Byers KF. Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation. J Adv Pract Oncol. 2019 Mar;10(2):167-174.
46.    Wagner LM. Profile of veliparib and its potential in the treatment of solid tumors. OncoTargets and Therapy 2015:8 1931–1939.
47.    Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Ben-Baruch NE, Werner TL, Cloven NG, Oaknin A, diSilvestro PA, Morgan MA, NAM JH, Leath III CA, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratjczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med 2019; 381:2403-2415.
48.    McCann KE, Hurvitz SA, McAndrew N. Advances in Targeted Therapies for Triple Negative Breast Cancer. Drugs. 2019; 79:1217–1230.
49.    Pernas S, Tolaney SM, Winer EP, Goel S. CDK4/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol. 2018; 10: 1-15.
50.    Cretella D, Fumarola C, Bonelli M, Alfieri R, La Monica S, Digiacomo G, Cavazzoni A, Galetti M, Generali D, Petronini PG. Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells. Rep. 2019; 9, 13014.
51.    Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019 Jul 25;381(4):307-316.
52.    McCartney A, Moretti E, Sanna G, Pestrin M, Risi E, Malorni L, Biganzoli L, Di Leo A. The role of abemaciclib in treatment of advanced breast cancer. Ther Adv Med Oncol. 2018; 10: 1758835918776925.
53.    Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2017 Jan 31; 8(5): 8921–8946.
54.    Synnott NC, McGowan PM, Pierce A, Kiely A, O'Donovan N, Crown J, Kiely PA, Duffy MJ. PRIMA-1MET (APR-246): A novel targeted therapy for triple negative breast cancer?. Journal of Clinical Oncology 2015 33:15_suppl, e12072-e12072.
55.    Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. European Journal of Cancer. 2017; 83:258-265.
56.    Bykov VJN, Issaeva N, Zache N, Shilov A, Hulterantz M, Bergman J, Selivanova G, Wiman KG. Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs. J Biol Chem. 2005 Aug 26;280(34):30384-91.  
57.    El Majzoub R, Fayyad-kazan M, El Dine AN, Makki R, Hamade E, Grée R, Hachem A, Talhouk R, Fayyad-kazan H, Badran B. A thiosemicarbazone derivative induces triple negative breast cancer cell apoptosis: possible role of miRNA 125a 5p and miRNA 181a 5p. Genes & Genomics. Genes & genomics. 2019; 41(Suppl 6).
58.    Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, Lovejoy DB, Sharpe PC, Bernhardt PV, Richardson SR. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
J Med Chem. 2009 Sep 10;52(17):5271-94.
59.    Bryant C, Rawlinson R, Massey J. Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer. 2014; 14: 570.
60.    Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del Mastro L, De Laurentiis M, Puglisi F, Arpino G. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treat Rev. 2018 Jul;68:102-110.  
61.    Rampurwala M, Wisinski KB, O’Regan R. Role of the Androgen Receptor in Triple-Negative Breast Cancer. Clin Adv Hematol Oncol. 2016 Mar; 14(3): 186–193
62.    Mina A, Yoder R, Sharma P. Targeting the androgen receptor in triple-negative breast cancer: current perspectives. Onco Targets Ther. 2017 Sep 20;10:4675-4685.
63.    Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; Translational Breast Cancer Research Consortium (TBCRC 011). Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013 Oct 1;19(19):5505-12.
64.    Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, Zhuang Y, Liu D, Lu SW, Kalari KR, Visscher DW, Copland JA, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Lou Z, Suman VJ, Weinshilboum R, Boughey JC, Goetz MP, Wang L. Targeting DNA methylation for treating triple-negative breast cancer. Pharmacogenomics. 2019 Nov; 20(16): 1151–1157.
65.    Mathe A, Wong-Brown M, Locke WJ, Stirzaker C, Braye SG, Forbes JF, Clark SJ, Avery-Kiejda KA, Scott RJ. DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients. Sci Rep. 2016, 6(33435).
66.    Butler C, Sprowls S, Szalai G, Arsiwala T, Saralkar P, Straight B, Hatcher S, Tyree E, Yost M, Kohler WJ, Wolff B, Putnam E, Lockman P, Liu T. Hypomethylating Agent Azacitidine Is Effective in Treating Brain Metastasis Triple-Negative Breast Cancer Through Regulation of DNA Methylation of Keratin 18 Gene. Transl Oncol. 2020 May 11;13(6):100775.
67.    Thakur V, Kutty RV. Recent advances in nanotheranostics for triple negative breast cancer treatment. J Exp Clin Cancer Res. 2019; 38(430): 1-22
68.    Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016; 6(8): 1609–1623
69.    El Guerran A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. Sci Rep. 2020; 10(6367).
70.    Bao B, Mitrea C, Wijesinghe P, Marchetti L, Girsch E, Farr RL, Boerner JL, Mohammad R, Dyson G, Terlecky SR, Bollig-Fischer A. Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. Sci Rep. 2017 Mar 10;7:44125.
71.    Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2012 Aug;134(3):1149-59. .
72.    Liao WS, Ho Y, Lin YW, Naveen Raj E, Liu KK, Chen C, Zhou XZ, Lu KP, Chao JI. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. Acta Biomater. 2019 Mar 1;86:395-405.
73.    Battaglin F, Dadduzio V, Bergamo F, Manai C, Schirripa M, Lonardi S, Zagonel V, Loupakis F. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. Expert Opin Biol Ther. 2017 Oct;17(10):1297-1308.  
74.    Bouché O, Abdelghani MB, Labourey JL, Triby S, Bensadoun RJ, Jouary T, Guetz GD. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer. World J Gastroenterol. 2019 Aug 7; 25(29): 4007–4018.
75.    Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez H, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Luci A, DeSynder SM, Tripathy D, Valero V, Ueno NT. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018;4(9):1207-1213.
76.    Lee JJX, Loh K, Yap YS. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2015 Dec; 12(4): 342–354.
77.    Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018 Jun;169(3):397-406.
78.    Ribbati D, Nico B, Ruggieri S, Tamma R, Simone G, Mangia A. Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer. Transl Oncol. 2016 Oct; 9(5): 453–457.
79.    Dent SF. The role of VEGF in triple-negative breast cancer: where do we go from here? Annals of Oncology. 2009; 20: 1615–1617.
80.    Greenberg S, Rugo HS. Triple-negative breast cancer: role of antiangiogenic agents. Cancer J. 2010 Jan-Feb;16(1):33-8.  
81.    Manso L, Moreno F, Márquez R, Castelo B, Arcediano A, Arroyo M, Ballesteros AI, Calvo I, Echarri MJ, Enrech S, Gómez A, González Del Val R, López-Miranda E, Martín-Angulo M, Martínez-Jañez N, Olier C, Zamora P. Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol. 2015 Apr;22(2):e51-60.
82.    Gui X, Li H, Song G, Shao B, Jiang H. Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report. Medicine (Baltimore). 2018 Nov;97(48):e13410.
83.    Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O’Donovan N, Crown J, Duffy MJ. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol. 2011 Oct;22(10):2234-40.
84.    Lou L, Yu Z, Wang Y, Wang S, Zhao Y. c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo. Cancer Sci. 2018 May;109(5):1648-1659.
85.    Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. 2011 Nov 1;17(21):6905-13.
86.    Tian J, Raffa FA, Dai M, Moamer A, Khadang B, Hachim IY, Bakdounes K, Ali S, Jean-Claude B, Lebrun JJ. Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells. Br J Cancer. 2018 Dec;119(12):1495-1507.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available